Repare Therapeutics (RPTX) Competitors $1.42 -0.02 (-1.39%) Closing price 07/7/2025 03:59 PM EasternExtended Trading$1.44 +0.02 (+1.34%) As of 07/7/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. ACB, NGNE, TVRD, BTMD, SLRN, TVGN, CGC, PRQR, NBTX, and YMABShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Aurora Cannabis (ACB), Neurogene (NGNE), Tvardi Therapeutics (TVRD), biote (BTMD), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. Its Competitors Aurora Cannabis Neurogene Tvardi Therapeutics biote Acelyrin Semper Paratus Acquisition Canopy Growth ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics Aurora Cannabis (NASDAQ:ACB) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more risk & volatility, ACB or RPTX? Aurora Cannabis has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Is ACB or RPTX more profitable? Aurora Cannabis has a net margin of 1.32% compared to Repare Therapeutics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.13% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis1.32% 0.13% 0.10% Repare Therapeutics N/A -78.12%-67.11% Do analysts rate ACB or RPTX? Repare Therapeutics has a consensus target price of $4.50, indicating a potential upside of 216.90%. Given Repare Therapeutics' higher probable upside, analysts clearly believe Repare Therapeutics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to ACB or RPTX? In the previous week, Aurora Cannabis and Aurora Cannabis both had 2 articles in the media. Aurora Cannabis' average media sentiment score of 0.00 equaled Repare Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repare Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, ACB or RPTX? Aurora Cannabis has higher revenue and earnings than Repare Therapeutics. Repare Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$246.72M1.01$1.63M$0.1140.27Repare Therapeutics$53.48M1.14-$84.69M-$3.01-0.47 Do insiders & institutionals believe in ACB or RPTX? 47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 11.5% of Repare Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAurora Cannabis beats Repare Therapeutics on 10 of the 15 factors compared between the two stocks. Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.76M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-0.4720.4427.2220.04Price / Sales1.14181.20380.3292.37Price / CashN/A41.7026.2128.59Price / Book0.407.397.945.55Net Income-$84.69M-$55.04M$3.17B$248.49M7 Day PerformanceN/A2.51%1.81%4.87%1 Month Performance-3.40%-0.21%1.28%6.63%1 Year Performance-55.76%3.41%33.57%20.38% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics2.0649 of 5 stars$1.42-1.4%$4.50+216.9%-55.2%$61.76M$53.48M-0.47180Gap DownACBAurora Cannabis0.0957 of 5 stars$4.24+2.2%N/A-8.1%$233.29M$246.72M38.551,130NGNENeurogene3.7708 of 5 stars$14.95-7.5%$46.17+208.8%-42.9%$230.48M$930K-3.4490TVRDTvardi TherapeuticsN/A$23.33-5.2%$71.50+206.5%N/A$230.37M$7.14M0.0080BTMDbiote3.0552 of 5 stars$4.02-4.3%$8.00+99.0%-46.0%$229.78M$197.19M6.59194SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135TVGNSemper Paratus Acquisition3.947 of 5 stars$1.25+0.8%$10.00+700.0%+71.4%$228.03MN/A0.003CGCCanopy Growth2.8321 of 5 stars$1.22flat$2.00+63.9%-81.1%$224.32M$225.65M-0.303,150Positive NewsPRQRProQR Therapeutics2.1391 of 5 stars$2.04flat$8.00+292.2%+25.9%$214.63M$20.46M-5.83180NBTXNanobiotix1.6739 of 5 stars$4.73+4.4%$8.00+69.1%-13.1%$213.34M$39.18M0.00100News CoveragePositive NewsGap UpYMABY-mAbs Therapeutics3.1136 of 5 stars$4.51-4.0%$15.60+245.9%-63.0%$212.83M$87.68M-7.05150 Related Companies and Tools Related Companies Aurora Cannabis Alternatives Neurogene Alternatives Tvardi Therapeutics Alternatives biote Alternatives Acelyrin Alternatives Semper Paratus Acquisition Alternatives Canopy Growth Alternatives ProQR Therapeutics Alternatives Nanobiotix Alternatives Y-mAbs Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
